Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Eight-Year Data for Opdivo Plus Yervoy Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously.

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #ASCO--Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial.

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Opdivo Plus Yervoy Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite.

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial

Altria

Interest rates have declined from the 2023 highs, and we are likely to see further reductions in the next couple of years. As rates decline, higher yielding stocks can rise in value as the hunt for yield returns. It makes sense to buy dividend stocks that are undervalued and pay you to wait for share price appreciation.

A Rare And Major Dividend Stock Buying Opportunity With Altria And Bristol Myers Squibb

Starbucks

Verizon

Updated economic information shows an increase in GDP and a decline in CPI, while producer prices dropped.

Dividend Harvesting Portfolio Week 150: $15,000 Allocated, $1,322.77 In Projected Dividends

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers.

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

AbbVie

American Tower

Ares Capital

BlackRock Science & Technology

Central Securities

Chevron

Enbridge

Home Depot

Intuit

JPMorgan Equity Premium Income ETF

Barings Corporate Investors

Medtronic

MPLX

Morgan Stanley

Microsoft

NextEra Energy

NXP Semiconductors

Realty Income Corp

PepsiCo

Parker-Hannifin

Regions Financial

Cohen & Steers Quality Income Realty Fund

Schwab US Dividend Equity ETF

Columbia Seligman Premium Technology Growth Func Inc

We outline an Income Strategy for creating a self-sufficient portfolio for retirees and income-focused investors with $1 million to generate a life-long income stream. We explain the benefits of generating income through dividends and distributions rather than selling shares for capital gains. We compare the results of backtesting an income strategy with index investing for the past 24 years, starting from the year 2000.

How To Invest $1 Million In Retirement For Life-Long Income

I discuss a cheap Big Pharma stock and its performance in the market. I provide an overview of the stock's history, including its R&D cycle, dividend and yield on cost history, and valuation. With Eliquis generating $11.78 Billion in revenue and Opdivo $8.24 Billion, that's almost $20 Billion in revenue at stake that needs to be slowly replaced.

Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal

Virtus InfraCap U.S. Preferred Stock ETF

Walgreens

The markets had a rough start to the year, with the S&P 500 and Nasdaq declining in the first week of January.

Dividend Harvesting Portfolio Week 149: $14,900 Allocated, $1,316.50 In Projected Dividends

Alphabet

iShares Nasdaq Biotechnology ETF

iShares Russell 2000 ETF

Karuna Therapeutics Inc

NVIDIA

Novo Nordisk

Novartis

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

Bullish Continuation in '24? 3 Market Areas to Watch

Agilent Technologies

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Disney

Estee Lauder

Emerson Electric

Etsy

Gilead Sciences

Huntington Ingalls Industries

Harley-Davidson

Honeywell

International Flavors & Fragrances

Kenvue

McDonald's

NIKE

Otis Worldwide

Pfizer

Polaris

Ross Stores

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map

Shares of Bristol-Myers Squibb Company have bottomed and offer an enticing valuation. Bristol-Myers Squibb has a highly profitable business, strong cash flow, and a low P/E ratio. Bristol-Myers is deploying capital to secure its future through acquisitions and building a robust pipeline.

Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also

Agenus

Compugen

GlaxoSmithKline

iTeos Therapeutics, Inc.

Merck

Arcus Biosciences

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Bristol Myers Squibb (BMY) concluded the recent trading session at $51.28, signifying a -0.98% move from its prior day's close.

Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Biotech ETFs Stage Solid Comeback at the Start of 2024

News for Bristol-Myers Stock (BMY)